Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.

Article Details

Citation

Copy to clipboard

Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkila EA

Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.

N Engl J Med. 1979 Nov 15;301(20):1073-6.

PubMed ID

226883 [ View in PubMed

]

Abstract

In 11 hypertriglyceridemic patients on hemodialysis, clofibrate (1 to 1.50 g per week) reduced plasma triglyceride (-40 +/- 20%, P less than 0.001), very-low-density-lipoprotein triglyceride (-44 +/- 20%, P less than 0.001) and very-low-density lipoprotein cholesterol (-39 +/- 25%, P less than 0.01), and it increased high-density-lipoprotein cholesterol (82 +/- 106%, P less than 0.005). Low pretreatment lipoprotein-lipase activity in adipose-tissue specimens and postheparin plasma increased to normal with clofibrate, whereas low hepatic triglyceride lipase activity did not change. The reduced very-low-density-lipoprotein triglyceride correlated with the increased lipoprotein-lipase activity in adipose tissue (rs = 0.792, P less than 0.02, n = 8) and postheparin plasma (rs = 0.851, P less than 0.02, n = 8), whereas increased high-density-lipoprotein cholesterol correlated with changes in this activity in adipose tissue (rs = 0.696, P less than 0.06) and post-heparin plasma (rs = 0.679, P less than 0.10). There was no correlation between changes in hepatic triglyceride lipase activity and plasma lipids during treatment. Reduced lipoprotein-lipase activity may cause hypertriglyceridemia and decreased high-density-lipoprotein cholesterol in patients on hemodialysis; clofibrate may correct these abnormalities by increasing lipoprotein-lipase activity to normal.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Clofibrate	Approved Investigational	VLDL triglycerides	decreased	Clofibrate decreases the level of VLDL triglycerides in the blood
Clofibrate	Approved Investigational	VLDL cholesterol	decreased	Clofibrate decreases the level of VLDL cholesterol in the blood
Clofibrate	Approved Investigational	HDL cholesterol	increased	Clofibrate increases the level of HDL cholesterol in the blood